MSB and Oaktree Conclude Refinancing of Senior Debt Facility
Filed with ASX · · 2 pages · English
Melbourne, Australia; November 22, and New York, USA; November 21, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has successfully refinanced its existing senior debt facility with a new US$90 million five year facility provided by funds managed by Oaktree Capital Management, L.P. (“Oaktree”). Mesobl
In the deck
Earlier from Mesoblast
- AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
- MSB Annual Financial Results and Operational Progress
- Mesoblast Update on Chronic Low Back Pain Program
- MSB Reports Q3 Financial Results and Operational Highlight
- COVID ARDS Trial Topline 60-Day Results
Later from Mesoblast
- Update on Novartis Agreement
- FDAs OTAT Agrees to Primary Endpoint for Back Pain
- Appendix 4C Quarterly Activity Report
- Ulcerative Colitis & Crohns Results Presented at ECCO
- Second Quarter Results Presentation
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast